化学制药板块震荡拉升，信立泰、向日葵双双涨停，康芝药业、海创药业-U、海辰药业、贝达药业、 盟科药业-U、键凯科技等跟涨。 ...

Core Viewpoint - The article highlights the increasing trend of listed companies in China venturing into cross-industry investments, particularly in the fields of humanoid robots and semiconductor industries, driven by the AI wave [3][4][5]. Group 1: Company Activities - Companies like Xiangrikui and Jinziham have recently made significant investments in the semiconductor sector, with Xiangrikui planning to acquire 100% of Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beide Pharmaceutical Co., Ltd. [3] - Jinziham announced plans to invest up to 300 million yuan in Zhongsheng Microelectronics to capitalize on opportunities in the AI and optical communication markets [3][4]. - Over 20 listed companies have announced their entry into the humanoid robot sector, while more than 10 have invested in the semiconductor industry this year [5]. Group 2: Market Reactions - Following announcements of cross-industry ventures, companies typically experience significant stock price increases. For instance, Xiangrikui's stock surged by 1083% over 16 trading days after its announcement [6]. - Tianpu Co. also saw its stock rise by 317.77% after announcing its entry into the semiconductor industry, with a total increase of 795% this year [7]. Group 3: Industry Insights - The AI revolution is driving a new wave of technological opportunities, prompting companies from various sectors, including pharmaceuticals and food, to explore cross-industry investments [4][8]. - While the trend is gaining momentum, experts caution that not all companies are suited for cross-industry ventures, and blind investments may carry potential risks [8].

（编辑 姚尧） 证券日报网讯 9月23日晚间，向日葵发布公告称，公司股票于2025年9月22日、2025年9月23日连续两个 交易日内日收盘价格涨幅偏离值累计超过30%，属于股票交易异常波动情况。公司前期披露的信息不存 在需要更正、补充之处。公司未发现近期公共传媒报道可能或已经对公司股票交易价格产生较大影响的 未公开重大信息。 ...

Core Viewpoint - The company has not identified any undisclosed significant information that may have impacted its stock trading price, despite recent abnormal fluctuations in stock trading [1] Group 1 - The company is planning to issue shares and pay cash to acquire assets while raising matching funds for related transactions [1] - There have been no significant changes in the company's operational situation or external business environment recently [1] - During the period of abnormal stock fluctuations, the company's controlling shareholder and actual controller did not engage in buying or selling the company's stock [1]

证券代码：300111 证券简称：向日葵 公告编号：2025—045 浙江向日葵大健康科技股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 浙江向日葵大健康科技股份有限公司（以下简称"公司"）股票于 2025 年 9 月 22 日、2025 年 9 月 23 日连续两个交易日内日收盘价格涨幅偏离值累计超过 30%，根据《深圳证券交易所交易规则》有关规定，属于股票交易异常波动情况。 二、公司关注并核实情况说明 针对本次公司股票交易异常波动，公司董事会通过自查，且对控股股东、实 际控制人书面发函就相关事项进行了核实，现将有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、公司未发现近期公共传媒报道可能或已经对公司股票交易价格产生较大 影响的未公开重大信息。 自本次交易预案披露以来，公司及相关各方积极推进本次交易的各项工作。 截至目前，本次交易涉及的审计、评估等工作尚未完成。待相关工作完成后，公 司将再次召开董事会审议本次交易的正式方案，披露重组报告书，并按照相关法 律法规的规定 ...

浙商证券股份有限公司 关于浙江向日葵大健康科技股份有限公司发行股份及支付现金 购买资产并募集配套资金暨关联交易的核查意见 浙商证券股份有限公司（以下简称"浙商证券"、"保荐人"）作为浙江向 日葵大健康科技股份有限公司（以下简称"向日葵"、"公司"）向特定对象发 行股票项目持续督导阶段的保荐人，根据《证券发行上市保荐业务管理办法》《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定，对公司拟发行股份及支付现金 购买资产并募集配套资金暨关联交易事项进行了审慎核查，并出具本核查意见： 一、关联交易概述 公司拟通过向上海兮噗科技有限公司（以下简称"上海兮噗"）等交易对方 发行股份及支付现金的方式购买其持有的漳州兮璞材料科技有限公司（以下简称 "兮璞材料"）100%股权，向绍兴向日葵投资有限公司（以下简称"向日葵投资"） 发行股份及支付现金的方式购买其持有的浙江贝得药业有限公司（以下简称"贝 得药业"）40%股权。本次交易完成后，兮璞材料和贝得药业将成为上市公司全 资子公司。具体情况如下： 1、基本情况 2 | 交易形式 | 发行股份及支付现金购买资 ...

Group 1 - The stock "向日葵" reached its daily limit increase of 20.00%, with a turnover rate of 32.42% and a trading volume of 2.75 billion yuan, showing a price fluctuation of 19.00% [1][2] - Institutional investors net sold 46.55 million yuan, while the total net selling from brokerage seats amounted to 29.56 million yuan [1][2] - The stock was listed on the Shenzhen Stock Exchange due to its closing price increase of 20.00%, with the top five trading departments collectively transacting 390 million yuan, including 157 million yuan in buying and 233 million yuan in selling, resulting in a net selling of 76.11 million yuan [2] Group 2 - The main capital outflow for the stock was 495 million yuan, with large orders contributing to a net outflow of 437 million yuan and a net outflow of 58.02 million yuan from larger funds [2] - Over the past five days, the main capital has seen a net outflow of 431 million yuan [2] - Specific trading data shows that the top buying department was Dongxing Securities with a purchase amount of 358.09 million yuan, while the top selling department was a specialized institutional seat with a selling amount of 472.40 million yuan [2]

Market Overview - The Shanghai Composite Index fell by 0.18% on September 23, with five industries experiencing gains, led by the banking and coal sectors, which rose by 1.52% and 1.11% respectively [1] - The social services and retail trade sectors saw the largest declines, down by 3.11% and 2.90% respectively [1] - The pharmaceutical and biotechnology industry also declined by 1.93% [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 996.85 billion yuan, with only three industries seeing net inflows: banking (14.00 billion yuan), construction and decoration (1.69 billion yuan), and coal (399.41 million yuan) [1] - The electronics industry experienced the largest net outflow, totaling 200.43 billion yuan, followed by the computer industry with a net outflow of 166.60 billion yuan [1] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector saw a net outflow of 81.15 billion yuan, with 474 stocks in the sector; 32 stocks rose while 441 fell [2] - The top net inflow stocks in this sector included Amgen Pharmaceuticals-U with a net inflow of 114.11 million yuan, followed by China National Pharmaceutical and Guangsheng Tang with inflows of 74.18 million yuan and 73.03 million yuan respectively [2] - The sector's outflow leaderboard featured WuXi AppTec with a net outflow of 65.79 million yuan, followed by Bory Pharmaceutical and Sunflower with outflows of 56.65 million yuan and 49.46 million yuan respectively [4]

向日葵今日涨停，龙虎榜数据显示，上榜营业部席位全天成交3.9亿元，占当日总成交金额比例为 14.18%。其中，买入金额为1.57亿元，卖出金额为2.33亿元，合计净卖出7610.5万元。具体来看，机构 买入69.41万元，卖出4723.99万元，合计净卖出4654.58万元。此外，东兴证券北京复兴路证券营业部、 国泰海通证券上海长宁区江苏路证券营业部分别买入3580.86万元、3084.93万元；浙商证券台州环城东 路证券营业部、国金证券成都高新区交子大道证券营业部分别卖出9701.06万元、2837.28万元。截至9月 23日收盘，向日葵涨20%，全天换手率达32.42%，振幅达19.16%，全天成交27.0亿元，近5个交易日累 计涨43.95%，近30个交易日累计涨80.3%。 ...

Group 1 - The core point of the article highlights that the trading volume of Sunflower has reached 1.142 billion yuan, marking the highest level since September 10, 2020 [2] - The latest stock price of Sunflower has increased by 6.05%, with a turnover rate of 13.61% [2] - The previous trading day's total transaction volume for the stock was 131 million yuan [2] Group 2 - Zhejiang Sunflower Health Technology Co., Ltd. was established on March 21, 2005, with a registered capital of 1.287 billion yuan [2]